APOPTOSIS OF PERIPHERAL BLOOD LYMPHOCYTES OF PROSTATE CANCER PATIENTS INDUCED BY IN VITRO IRRADIATION
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-4-2019-g.8142Keywords:
prostate cancer, radiotherapy, individual radiation sensitivity, peripheral blood lymphocytes, in vitro X-ray test-irradiation, reactive oxygen species, chromosomal aberrations, prostate-specific antigen.Abstract
High-dose radiation therapy required for treating radioresistant tumors such as prostate cancer (PC) could entail the increased risk of postradiation complications. The individual radiation sensitivity (IRS) should be taken into account for predicting side effects of radiation therapy. The assessment of apoptosis in peripheral blood lymphocytes (PBL) of patients may be considered as one of the methods for IRS estimation. Aim: To study the level of apoptosis induced by in vitro test-irradiation of PBL isolated from PC patients throughout the course of radiation therapy and its probable correlation with content of reactive oxygen species (ROS), the frequency of postradiation chromosomal abnormalities and several clinical indices. Object and methods: 16 PC patients, predominantly stages II–III and treated with radiotherapy were included in the study. Apoptosis level was estimated in PBL isolated prior to the treatment, after the first fraction of therapeutic irradiation and after the completion of the treatment. Apoptotic fraction in PBL was determined following 48-h culture of isolated cells without mitogen stimulation both in untreated samples and in samples subjected to in vitro X-ray test-exposure prior to the initiation of culture. Fe2+ induced ROS generation in blood plasma was measured with N,N-diethyl-paraphenylenediamine. Metaphase analysis of chromosomal aberrations was provided following the "provocative" X-ray exposure of PBL culture at the end of the G2-phase of the mitotic cycle (1.5 Gy). Results: The correlation between the values of the apoptotic fraction in PBL samples with/without in vitro test-irradiation has been found both in PBL isolated prior to the treatment (r = 0.88), and after the first fraction of the therapeutic irradiation (r = 0.77). The wide range of the apoptotic index in PBL from PC patients suggests the substantial variability of IRS. The apoptotic fraction in PBL correlated with ROS level in blood plasma in the samples obtained following the first fraction of the therapeutic irradiation (r = 0.77) but not in the samples obtained prior to the beginning of the treatment. The data of G2-assay did not correlate with apoptosis level in PBL. Conclusions: The apoptotic indices in in vitro test-irradiated PBL isolated from PC patients subjected to radiotherapy correlated with those in PBL cultured without test-irradiation. Only weak correlation is revealed between the level of spontaneous apoptosis and ROS level in blood plasma. The level of spontaneous apoptosis does not correlate with clinical indices.
References
Fedorenko ZP, Michailovich YY, Goulak LO, et al. Cancer in Ukraine 2016-2017. Incidence, mortality, activities of oncological service. Bulletin of National Cancer Registry of Ukraine, vol 19. Kyiv: National Cancer Institute of Ukraine, 2018. 82 p.
Alekseev BYa, Kaprin AD, Matveev VB, Nyushko KM. Clinical guidelines for the diagnosis and and treatment of prostate cancer. Russian Association of Oncologists. Moscow: NN Blokhin National Medical Research Centre of Oncology of the Health Ministry of Russia, 2014. 43 p. (in Russian).
Basic Clinical Radiobiology, 4th Ed. Joiner MC, van der Kogel A, Eds. Boca Raton, FL: CRC Press; 2009. 375 p.
Ciszewski WM, Tavecchio M, Dastych J, Curtin NJ. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Res Treat 2014; 143 (1): 47–55.
Borgmann K, Haeberle D, Doerk T, et al. Genetic determination of chromosomal radiosensitivities in G0- and G2-phase human lymphocytes. Radiother Oncol 2007; 83 (2): 196–202.
Domina EA, Druzhyna MO, Ryabchenko NM. Individual radiosensitivity of a person. Kyiv: Logos, 2006. 126 p. (in Ukrainian).
Kovalev EE, Smirnova OA. Estimation of Radiation Risk Based on Concept of Individual Variability of Radiosensitivity. Bethesda: Armed Forces Radiobiology Research Institute, 1996. 198 p.
Pernot E, Hall J, Baatout S, et al. Ionizing radiation biomarkers for potential use in epidemiological studies. Mutat Res 2012; 751 (2): 258–86.
Domina EA, Philchenkov A, Dubrovska A. Individual response to ionizing radiation and personalized radiotherapy. Crit Rev Oncogen 2018; 23 (1-2): 69–92.
Boreham DR, Gale KL, Maves SR, et al. Radiation-induced apoptosis in human lymphocytes: potential as a biological dosimeter. Health Phys 1996; 71 (5): 685–91.
Radford IR, Murphy TK. Radiation response of mouse lymphoid and myeloid cell lines. Part III. Different signals can lead to apoptosis and may influence sensitivity to killing by DNA double-strand breakage. Int J Radiat Biol 1994; 65 (2): 229–39.
Ozsahin M, Ozsahin H, Shi Y, et al. Rapid assay of intrinsic radiosensitivity based on apoptosis in human CD4 and CD8 T-lymphocytes. Int J Radiat Oncol Biol Phys 1997; 38 (2): 429–40.
Ozsahin M, Crompton NE, Gourgou S, et al. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res 2005; 11 (20): 7426-33.
Brzozowska K, Pinkawa M, Eble MJ, et al. In vivo versus in vitro individual radiosensitivity analysed in healthy donors and in prostate cancer patients with and without severe side effects after radiotherapy. Int J Radiat Biol 2012; 88 (5): 405–13.
Vogin G, Merlin JL, Rousseau A, et al. Absence of correlation between radiation-induced CD8 T-lymphocyte apoptosis and sequelae in patients with prostate cancer accidentally overexposed to radiation. Oncotarget 2018; 9 (66): 32680–9.
Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019; 29 (5): 347–64.
Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139 (2): 271–9.
Hayashi I, Morishita Y, Imai K, et al. High-throughput spectrophotometric assay of reactive oxygen species in serum. Mutat Res 2007; 631 (1): 55–61.
Domina EA, Mikhailenko VM, Glavin OA, Makovetska LI. Detection of individuals with high individual sensitivity to protect their genome from exposure to background radiation doses. Methodical Recommendations. Kyiv: DIA, 2018. 30 p. (in Ukrainian).
Glavin OA, Domina EA, Mikhailenko VM, Makovetska LI. Determination of correlation between the state of pro- and antioxidant processes in the blood of patients with prostate cancer and chromosomal instability of blood lymphocytes. Oncology (Kyiv) 2019; 21 (2): 135–141 (in Ukrainian).
Pelevina II, Aleshchenko AV, Antoshchina MM, et al. The content of ROS in blood lymphocytes of healthy individuals, individuals irradiated as a result of chernobyl disaster and patients with prostate cancer. Radiats Biol Radioecol 2016; 56 (5): 469–74 (in Russian).
Sarsour EH, Kumar MG, Chaudhuri L, et al. Redox control of the cell cycle in health and disease. Antioxid Redox Signal 2009; 11 (12): 2985–3011.
Sycheva IV. Treatment of radiation-induced pelvic damage after radiation therapy for prostate cancer. Sib J Oncol 2018; 17 (3): 64–71. (in Russian). [Cited 2019 March 25]. Available from: https://www.siboncoj.ru/jour/article/view/765/539.
Uemura N, Kondo T. Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer. World J Gastrointest Pathophysiol 2014; 5 (3): 322–34.
